Staphylococcal superantigen-like (SSL) proteins, one of the major virulence factor families produced by Staphylococcus aureus, were previously demonstrated to be immune evasion molecules that interfere with a variety of innate immune defences.
| INTRODUCTION
The Gram-positive bacterium Staphylococcus aureus (S. aureus) is an opportunistic human pathogen that causes a wide range of diseases from mild skin infections to more serious life-threatening wound and systemic infections (Spaan, Surewaard, Nijland, & van Strijp, 2013) .
In order to successfully invade and colonise the human host, S. aureus secretes a large arsenal of immune evasion molecules that specifically target components of the human innate and adaptive immune systems (Foster, 2005; Lewis & Surewaard, 2018; Thammavongsa, Kim, Missiakas, & Schneewind, 2015) . These secreted proteins interfere with a range of immune defences, which can be grouped into four categories: blocking, degradation, cell lysis, and modulation (Koymans, Vrieling, Gorham, & van Strijp, 2016) . Despite the functional differences and diversity in targets, the staphylococcal immune evasion proteins are secreted proteins that show remarkable resemblances. These proteins contain very conserved structural properties (Jongerius et al., 2007) . They are often small, varying in size between 8 and 35 kDa, and have extreme isoelectric points (above 9 or below 5). Another common property of these proteins is that they are located on genomic clusters with other virulence factors. The secretome of S. aureus is predicted to contain up to 270 proteins, of which over 35 staphylococcal evasion molecules have been described (Koymans et al., 2016) . Identification and characterisation of these secreted proteins will lead to a better understanding of the S. aureus pathological processes.
Neutrophils play a crucial role in protecting the host from S. aureus infections (van Kessel, . Inherited or acquired neutrophil dysfunction, such as leukocyte adhesion deficiency and chronic granulomatous disease, leads to an increased risk of severe S. aureus infections (Voyich et al., 2005) . Disruption of physical barriers and invasion of S. aureus initiate the release of proinflammatory signals that promote neutrophil adherence to the vascular endothelium, extravasation, and migration from the bloodstream towards to the site of infection (Spaan, Surewaard, et al., 2013) . However, S. aureus can subvert neutrophil functions via the secretion of proteins that inhibit neutrophil recruitment and activation (Bestebroer et al., 2007; Chavakis et al., 2002) . A variety of immune evasion proteins have been identified that specifically target neutrophil surface receptors. Some immune evasion proteins inhibit proinflammatory receptors such as chemotaxis inhibitory protein of S. aureus (CHIPS;
de Haas et al., 2004) , formyl peptide receptor-like 1 inhibitory protein (FLIPr) , and the homologue FLIPr-like (FLIPrL; Prat et al., 2009; Prat, Bestebroer, de Haas, van Strijp, & van Kessel, 2006) . Other immune evasion proteins serve as toxins that use surface receptors to specifically lyse leukocytes, such as the bicomponent toxins (PVL, LukAB, and LukED; Alonzo et al., 2013; DuMont et al., 2013; Spaan, Henry, et al., 2013) and phenol soluble modulins (PSMs; Surewaard et al., 2012) . In addition, the PSMs act as potent neutrophil chemoattractants via human formyl peptide receptor 2 (FPR2; Kretschmer et al., 2010; Weiss et al., 2017) . The FPR2 is a G protein-coupled receptor (GPCR) and a member of the FPR family together with the archetype formyl peptide receptor 1 (FPR1). Both receptors are present on neutrophils and myeloid cells and are considered as sensors for microbe-associated molecular patterns (MAMPs).
In contrast to the FPR1, the FPR2 is a promiscuous receptor with various unrelated ligands, which include peptides, parts of proteins, lipids, and small molecules, resulting in different intracellular responses in a ligand-specific manner (Cattaneo, Parisi, & Ammendola, 2013) .
Another group of secreted proteins, of which many are involved in immune evasion, is the staphylococcal superantigen-like (SSL) proteins (Thammavongsa et al., 2015) . SSLs are a family of 14 proteins with structural similarity to staphylococcal superantigens but lack the functional T-cell receptor binding domain and therefore exhibit no superantigenic activity (Fraser & Proft, 2008) . Moreover, structurally, the C-terminal β-grasp domain of these SSL proteins show homology to other staphylococcal immune evasion proteins such as CHIPS.
SSL1 to SSL11 are encoded on staphylococcal pathogenicity island 2 whereas SSL12, SSL13, and SSL14 are found on the immune evasion cluster 2 (Jongerius et al., 2007; Kuroda et al., 2001) . The SSL gene cluster is expressed in all human and animal isolates of S. aureus examined to date, indicating that it is very stable and evolutionary important cluster for the organism (Fitzgerald et al., 2003; Kuroda et al., 2001; Smyth, Meaney, Hartigan, & Smyth, 2007) . Furthermore, antibodies against the SSLs are detected in human serum, indicating that they are expressed in vivo and may play a role during infection (AlShangiti, Nair, & Chain, 2005; Fitzgerald et al., 2003) . Even though the SSLs are highly conserved and involved in innate immune evasion, they have distinct functions (Fraser & Proft, 2008) . It was reported previously that several SSL members located on the main cluster (SSL3, SSL5, SSL6, SSL7, and SSL10) are involved in inhibition of host immune responses (Baker et al., 2007; Bestebroer et al., 2009; Langley et al., 2005; Walenkamp et al., 2009 ). SSL3 and SSL4 have been described as toll-like receptor 2 inhibitors and prevent neutrophil activation (Bardoel et al., 2012; Hanzelmann et al., 2016) . SSL5 interacts with neutrophil surface receptor CD162 and reduces neutrophil migration (Baker et al., 2007; Bestebroer et al., 2007) . SSL6 was identified to interact with CD47 by screening a S. aureus secretome phage display library for binding to isolated human neutrophils (Fevre et al., 2014) . SSL7 binds to complement C5 and therefore prevents C5a production (Bestebroer, Aerts, et al., 2010) . In addition, SSL7 and SSL10 are associated with blocking complement activation by targeting IgA and IgG, respectively (Bestebroer, Aerts, et al., 2010; Patel, Wines, Langley, & Fraser, 2010) . In contrast, none of the SSLs on the minor cluster (SSL12-SSL14) have been functionally characterised.
In this study, we set out to identify new S. aureus proteins that interact with human neutrophils using a S. aureus secretome phage display library. In combination with whole genome sequencing, SSL13 was identified to bind human neutrophils. We show that binding to human neutrophils is FPR2 dependent. Through this interaction, SSL13 activates neutrophils and acts as a chemoattractant. Table S2 . There is a large increase in read frequency after selection.
The highest read frequency with 883 reads encoding seven unique sequences is annotated as a transmembrane protein involved in mannitol transport. The selection of transmembrane proteins when performing phage display selection on cells was also observed in earlier phage selections in our lab (data not shown). The presence of membranes appear to select for transmembrane domains especially transporter proteins such as ABC transporters. The second highest hit with 196 reads and four different clones identified the recently described S. aureus protein (SPIN) that binds neutrophil MPO and promotes the intracellular survival of S. aureus after phagocytosis (de Jong et al., 2017) . Of the total of 61 identified proteins, 12 (20%) were described to play a role in host-microbe interaction. Of these, 11 were already functionally characterised, and for one protein, SSL13, no known function has been described. The fact that SSL13 was identified in this selection suggests that it is involved in binding to neutrophils or its components.
| SSL13 specifically interacts with human neutrophils
To confirm that SSL13 interacts directly with human neutrophils, a threefold dilution series of recombinant SSL13 with an N-terminal His tag was incubated with human leukocytes isolated from healthy donors. His-tagged SSL7 and SSL5 were included as negative and positive control neutrophil-binding proteins, respectively (Bestebroer et al., 2007; Laursen et al., 2010) . We observed that SSL13 interacts with human neutrophils and monocytes in a dose-dependent manner, (Jongerius et al., 2007) . The effect of SSL13 on CD11b and CD62L expression was evaluated by flow cytometry. We observed that SSL13 enhanced the surface expression of CD11b and simultaneously down-regulated the expression of CD62L in a dose-dependent manner (Figure 2a, b) . In addition to the altered expression of surface adhesion molecules, activated neutrophils also exhibit intracellular release of calcium (Hamm, 1998) . We therefore measured the intracellular release of calcium after neutrophil exposure to a range of SSL13 concentrations (23-740 nM). In concordance with the cell receptor expression assay, our calcium flux data showed that SSL13 induces a transient dose- 
| SSL13 specifically binds and activates FPR2
As SSL13 induced a rapid and transient release of intracellular Ca 2+ , we examined whether SSL13 acts through a GPCR . PTX is a general antagonist of GPCR activation and therefore blocks the release of intracellular Ca 2+ (Welin et al., 2015) . For this purpose, neutrophils were preincubated with or without PTX for 1 hr at 37°C with CO 2 and then stimulated with 370-nM SSL13 or fMLP as a reference PTX-sensitive stimulus (Bokoch & Gilman, 1984; Lad, Olson, & Smiley, 1985) . Figure 3a shows that PTX can block both SSL13-and fMLP-induced neutrophil activation, which confirms that SSL13 utilises a PTX-sensitive GPCR to induce this response.
To further investigate the responsible receptor, a set of wellcharacterised agonists and antagonists of neutrophil GPCRs were tested, including those for FPR1 and FPR2, leukotriene B4 receptor (BLTR1), platelet activating factor receptor, complement C5a receptor, and the interleukin 8 receptors CXCR1 and CXCR2. We found that an FLIPr also slightly inhibited the FPR1 activation, the control protein CHIPS, which specifically inhibits FPR1 (Prat et al., 2009) , had no effect on SSL13-mediated neutrophil activation ( Figure 3c ). Together, these experiments indicate that SSL13 elicits calcium fluxes in human neutrophils via FPR2.
To further confirm that FPR2 is the receptor for SSL13, we used HL60 cells stably transfected with or without human FPR2 (Christophe, Karlsson, Rabiet, Boulay, & Dahlgren, 2002; Dahlgren et al., 2000) . Binding of FITC-labelled SSL13 was only observed for HL60/ FPR2 and not for control HL60 cells (Figure 3d ). Furthermore, in order FIGURE 1 SSL13 binds to human neutrophils, monocytes, but not lymphocytes. Peripheral blood leukocytes were incubated with a threefold dilution series of His-SSL13 for 30 min at 4°C. Binding was detected with anti-His-FITC and analysed by flow cytometry. The different cell populations were identified based on scatter parameters. His-SSL5 and His-SSL7 are positive and negative controls for binding, respectively (a-c).
Error bars are SEM of three biological replicates analysed in duplicate to evaluate the role of FPR2 in recognising SSL13, we analysed the intracellular Ca 2+ response to SSL13 of HL60 with or without FPR2. 
| SSL13 is involved in chemoattractant-induced oxidative burst and degranulation of neutrophils
Triggering FPR2 induces many neutrophil effector functions, including chemotaxis, exocytosis, and superoxide generation (Fu et al., 2006) . To investigate whether SSL13 is a chemoattractant, neutrophil migration was measured in a 96-multiwell transmembrane system. Indeed, SSL13 stimulated chemotaxis of human neutrophils in a dose-dependent manner (Figure 4a ). Moreover, SSL13-induced chemotaxis in human neutrophils can be blocked by the FPR2 antagonist FLIPr (Figure 4b ).
To examine whether SSL13 is involved in FPR2-induced oxidative burst, a reactive oxygen species (ROS) assay was performed. The peptides WKYMVM and MMK-1 can both induce FPR2-mediated ROS production, although WKYMVM is more potent and was therefore used as control in our experiment (Karlsson et al., 2009) . Our data show that SSL13 induced a modest oxidative burst compared with the control FPR2 specific peptide WKYMVM (Figure 4c ), but both SSL13-and WKYMVM-induced oxidative burst in human neutrophils could be blocked by FLIPr (Figure 4c ). Furthermore, we tested whether SSL13 could induce neutrophil degranulation by measuring MPO activity in stimulated cell supernatant. MPO is one of the most abundant granule proteins in neutrophils and is efficiently released into the extracellular space during degranulation (Borregaard, 2010) .
Indeed, SSL13-induced neutrophil degranulation (Figure 4d ). Taken together, the functional outcomes of SSL13-induced neutrophil activation include chemotaxis, ROS production, and neutrophil degranulation pointing towards a proinflammatory response of neutrophils to this staphylococcal protein.
To test whether SSL13 could act intracellular and is produced by S. aureus after uptake by human neutrophils, we generated a GFP promoter construct. Because SSL13 is part of an operon together with SSL12 and SSL14, the SSL12-13-14 promoter was cloned in front of GFP and transformed into S. aureus Newman. We did not observe and PSMα (Surewaard et al., 2012 ; data not shown here).
2.5 | SSL13 is not able to efficiently activate mouse neutrophils (Figure 5b ). In contrast, the specific FPR2 agonistic peptide WKYMVM showed similar activation ability to both human and murine neutrophils (Figure 5c ). However, we were unable to detect any SSL13 binding to murine neutrophils (data not shown).
Because there was a minimal but specific activation of mouse neutrophils, we tested whether SSL13 can provoke a neutrophil influx after injection of SSL13 into the mouse-abdominal cavity. We (Torres et al., 2007) . We also did not observe SSL13 expression, using a GFP promotor reporter construct, under standard bacterial cell culture or after uptake by neutrophils.
SSL13 is not the only secreted molecule from S. aureus that is able to activate neutrophils. PSMs, which are small peptides secreted by S. aureus, with a completely different structure compared with SSL13, are known to activate and attract both human and mouse neutrophils via FPR2 (Kretschmer et al., 2010; Surewaard et al., 2012; Weiss et al., 2017) . In addition to this, micromolar concentrations of PSM have cell lytic activity, which is independent from FPR2. Serum can fully block PSMs functions in both the cell lysis and FPR2-mediated neutrophil activation (Surewaard et al., 2012) .
However, SSL13 activity was not inhibited by serum and is not cytotoxic for neutrophils ( Figure S5 ). In contrast to PSMs, SSL13 showed a high degree of human specificity and was not able to efficiently activate mouse neutrophils. Another difference is the regulation and expression of PSMs, which was shown to be induced after uptake by neutrophils (Surewaard et al., 2012) . So we believe that this agonist is regulated differently from the PSMs, and thereby 
| Reagents and antibodies
Monoclonal antibody (mAb) anti-His tag (clone AD1.1.10, FITClabelled) was purchased from LS Biosciences, and anti-CD62L (clone Dreg-56, FITC-labelled) and anti-CD11b (clone ICRF44, APC-labelled)
were purchased from BD. The peptide MMK-1 (H-LESIFRSLLFRVM-OH) was synthesised by Sigma, and WKYMVM was synthesised by Bachem AG (Switzerland). WRWWWW-NH2 (WRW4) and Pertussis toxin (PTX) were purchased from Tocris. Formyl-methionyl-leucyl phenylalanine (fMLP), tumour necrosis factor α, and cytochalasin B
were from Sigma-Aldrich. Fluo-3-AM (acetoxymethyl ester) and Calcein-AM were purchased from Thermo Fisher.
| Cloning, expression, and purification of recombinant proteins
FLIPr, FLIPr-like, and N-terminal His-tag labelled SSL13 (His-SSL13) were cloned, expressed, and purified as described (de Jong et al., 2017; Prat et al., 2009 ). For SSL13, primers were designed without signal peptide according to the published sequence of the gene NWMN_1076 for cloning into modified N-His6-TEV-(g)-pRSET vector (de Jong et al., 2017) . SSL13 was amplified from genomic DNA of S. aureus subsp. aureus strain Newman using the following primers:
5′-CGGGATCCCAATTTCCTAATACACCTATC-3′ and 5′-ATATGCGG CCGCTTAGTTTGATTTTTCGAG-3′. Restriction enzyme recognition sites are underlined. Recombinant protein was generated in Escherichia coli Rosetta Gami (DE3) plysS by induction with 1-mM isopropyl β-D-1-thiogalactopyranoside (Roche). His-tagged protein was isolated under native purification conditions using a 5-ml HiTrap chelating HP column (GE Healthcare) with an imidazole gradient (10-250 mM; Sigma-Aldrich). The purified protein was analysed on a 12.5% SDS-PAGE gel and showed one band corresponding to a mass of 26.8 kD ( Figure S1 ). For direct fluorescent labelling, His-SSL13 was mixed with 0.1-mg ml −1 FITC (Sigma-Aldrich) in 0.1-M carbonate buffer (pH 9.5) for 1 hr at 4°C and subsequently separated from free FITC by overnight dialysis against PBS.
| Cells
Human leukocytes were isolated from human heparinised blood as described (Fevre et al., 2014) Integres, Grenoble, France). Cells were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100-μg ml −1 streptomycin, and 100-units ml −1 penicillin.
| Phage library construction and phage production
A S. aureus secretome phage display library was created as described earlier (Fevre et al., 2014) . Briefly, genomic DNA from S. aureus strain Newman was mechanically fragmented and fragments were cloned into the pDJ01 secretome phagemid vector (Fevre et al., 2014) and transformed into TG1 E. coli. Phages lacking an active pIII protein were produced overnight by coinfection with Hyperphage® helper phages (Progen) at a multiplicity of infection of 10. Phages were purified and concentrated using Polyethylene glycol (PEG) precipitation and resuspended in PBS to yield a final concentration of 2 × 10 11 phages ml −1 .
| Phage selection on isolated human neutrophils
One millilitre of phage library was mixed with 1-ml isolated human 
| Phage library sequencing
Because the phage library was created using a pIII deficient helper phage, it consists of non-infectious phage particles. Therefore, traditional phage selection with multiple rounds of selection and amplification is not possible and the library was analysed by genome sequencing using the Illumina MiSeq System. In order to add the MiSeq adapters to the isolated phage DNA, a polymerase chain reaction was performed on the precipitated DNA using Phusion® HF Polymerase (New England Biolabs), according to the manufacturer's recommendations. The primers were designed for compatibility with the Illumina MiSeq v2 sequencing kit (Table S1 for primer sequences). The polymerase chain reaction product was purified using gel purification on an Ultra-pure 2% agarose gel, and the purified DNA was quantified on a Qubit 4 Fluorometer (Thermo Fischer Scientific).
The purified sample was run on a 1% agarose gel to determine purity and determine mean fragment size.
Sequencing was performed by loading 3pM of the library onto a MiSeq v2 2x250bp sequencing kit and ran on an Illumina MiSeq System according to manufacturer's instructions. Sequence data were deposited in ENA under study accession number: PRJEB26168.
| His-SSL13 binding assay
To 
| Chemotaxis
Neutrophil migration was measured in a 96-multiwell transmembrane system (ChemoTX; Neuro Probe) using an 8-μm pore size polycarbonate membrane 
| Myeloperoxidase (MPO) release
Neutrophils were treated for 10 min with cytochalasin-B and tumour necrosis factor α with gently shacking and, without wash, subsequently incubated with buffer only, SSL13, or fMLP. Cells were centrifugated at 500×g for 10 min and supernatant collected for MPO activity measurement (van Kessel, van Strijp, & Verhoef, 1991) .
Therefore, 10-μl sample was mixed with o-dianisidine substrate and H 2 O 2 in phosphate buffer at pH 6.0 and measured continuously for 30 min at 37°C in a plate reader (FLUOstar Omega) at 450 nm.
| Neutrophil oxidative burst assay
Horseradish peroxidase and isoluminol were used as a sensitive measure of the human neutrophil oxidative burst as described (Dahlgren, Karlsson, & Bylund, 2007; Önnheim, Bylund, Boulay, Dahlgren, & Forsman, 2008 
| Mouse experiments
In the mouse peritonitis model, 100-μg SSL13 in 0.5-ml PBS was injected into the peritoneum of 6-to 8-week-old female CD-1 mice. At 4 hr later, the mice were euthanised by cervical dislocation and abdominal cavities washed two times with 5 ml of RPMI medium containing 0.1% HSA and 5-mM EDTA. In total, 8 to 9 ml of peritoneal fluid was recovered and centrifuged at 1,200 r.p.m. for 10 min to collect the exudate cells. Cell pellets were resuspended in 500-μl buffer and counted with trypan blue in a TC20 automated cell counter (Bio-Rad). Before immunostaining, cells were first preincubated with 100-μg ml −1 normal goat IgG for 15 min.
We stained the samples with APC-conjugated antibody to mouse CD45 (leukocytes marker), PE-conjugated antibody to mouse Gr1
(neutrophil marker), and FITC-conjugated antibody to mouse F4/80
(macrophage marker). Samples were analysed on a flow cytometer.
Mouse neutrophils were isolated from bone marrow as described previously (Boxio, Bossenmeyer-Pourié, Vanderesse, Dournon, & Nüsse, 2005) . Briefly, a bone marrow cell suspension was collected by flushing the femurs and tibias with 10 ml of cold HBSS + 15-mM EDTA + 30-mM Hepes + 0.1% HSA. A two-layer Percoll density gradient (2 ml each in PBS) composed of 81% and 62.5% was used to enrich neutrophils from the total leucocyte population.
Interphase between 62.5% and 81% was collected. Cells were washed once with buffer and resuspended in RPMI-1640 with 0.1% HSA.
Calcium fluxes in mouse neutrophils were determined as described above for human neutrophils with final concentrations of 10, 3, 1, 0.3, 0.1, and 0.03 nM of WKYMVM and 1,000, 300, 100, 30, 10, and 3 nM of SSL13.
Mouse neutrophil-binding assays were conducted essentially as described for human neutrophils.
